Shield Therapeutics PLC Result of AGM (9250S)
28 June 2018 - 8:56PM
UK Regulatory
TIDMSTX
RNS Number : 9250S
Shield Therapeutics PLC
28 June 2018
Shield Therapeutics plc
("Shield" or the "Company")
Result of 2018 Annual General Meeting
London, UK, 28 June 2018. Shield Therapeutics plc (LSE:STX), a
commercial stage pharmaceutical company, with a focus on addressing
iron deficiency, is pleased to announce that at its Annual General
Meeting held on 27 June 2018, shareholders passed all of the
ordinary and special resolutions. The full text of each resolution
is contained in the Notice of AGM, which is available on the
Company's website.
-Ends-
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive
Officer
Karl Keegan, Interim Chief
Financial Officer
Nominated Adviser and Joint
Broker
Liberum Capital Limited
Christopher Britton/Steve
Pearce +44 (0)20 3100 2222
Joint Broker
Peel Hunt LLP + 44 (0)20 7418
James Steel/Christopher Golden 8900
Financial PR Advisor
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott/Matthew
Neal
About Shield Therapeutics plc
Shield Therapeutics is a commercial stage pharmaceutical
company, delivering innovative specialty pharmaceuticals to address
patients' unmet medical needs. Our clear purpose is to help our
patients become people again, by enabling them to enjoy the things
that make the difference in their everyday lives. The Group has a
marketed product, Feraccru(R), for the treatment of all adults with
iron deficiency with or without anaemia which has exclusive IP
rights until the mid-2030's. For more information please visit
www.shieldtherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGFKFDPKBKDQAB
(END) Dow Jones Newswires
June 28, 2018 06:56 ET (10:56 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024